Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SHE:300255)

China · Delayed Price · Currency is CNY

25.85

+0.93 (3.73%)

Jun 18, 2026, 3:04 PM CST

-51.03% (1Y)

Market Cap	23.76B +0.6%
Revenue (ttm)	872.53M -12.3%
Net Income	-355.81M
EPS	-0.39
Shares Out	919.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,875,988
Open	35.15
Previous Close	24.92
Day's Range	24.60 - 35.15
52-Week Range	24.40 - 71.71
Beta	0.29
Analysts	Buy
Price Target	9.00 (-65.18%)
Earnings Date	Aug 21, 2026

About SHE:300255

Hebei Changshan Biochemical Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, marketing, and sale of drugs for cardiovascular, cerebrovascular, diabetes, and cancer in China and internationally. It offers heparin sodium, calcium, and lithium, as well as heparinoid, LMW heparins, and sodium hyaluronate; dalteparin sodium, enoxaparin sodium, nadroparin calcium, and heparin sodium injections, as well as sildenafil citrate tablet; and albenatide. The company is also involved in technology de... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1992

Employees 1,194

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300255

Full Company Profile

Financial Performance

In 2025, SHE:300255's revenue was 875.13 million, a decrease of -15.10% compared to the previous year's 1.03 billion. Losses were -357.90 million, 43.5% more than in 2024.

Financial Statements